



ASX ANNOUNCEMENT

Results of General Meeting

Sydney, 5 July 2018: Actinogen Medical (ASX: ACW) advises that the Company held its General Meeting today, 5 July 2018 at 10.30 am (AEST).

The resolutions voted were in accordance with the Notice of General Meeting previously advised to the Australian Securities Exchange.

Further information, required by Section 251AA(2) of the Corporations Act 2001 (Cth), is attached.

Yours faithfully

A handwritten signature in black ink, appearing to read "Peter Webse", is positioned above the printed name and title.

Peter Webse
Company Secretary

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11 β -HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.

GENERAL MEETING
Thursday, 5 July, 2018

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution	Manner in which the securityholder directed the proxy vote (as at proxy close):				Manner in which votes were cast in person or by proxy on a poll (where applicable)		
	Votes <i>For</i>	Votes <i>Against</i>	Votes <i>Discretionary</i>	Votes <i>Abstain</i>	<i>For</i>	<i>Against</i>	<i>Abstain **</i>
1 RATIFICATION OF TRANCHE 1 PLACEMENT UNDER LISTING RULE 7.1 CAPACITY	217,358,799	933,322	831,148	0	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
2 RATIFICATION OF TRANCHE 1 PLACEMENT UNDER LISTING RULE 7.1A CAPACITY	217,358,799	933,322	831,148	0	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
3 AUTHORITY TO ISSUE TRANCHE 2 PLACEMENT SHARES	216,960,527	1,331,594	831,148	0	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item